Samanta Cupini

1.6k total citations
35 papers, 956 citations indexed

About

Samanta Cupini is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Samanta Cupini has authored 35 papers receiving a total of 956 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 14 papers in Hepatology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Samanta Cupini's work include Colorectal Cancer Treatments and Studies (29 papers), Cancer Treatment and Pharmacology (19 papers) and Hepatocellular Carcinoma Treatment and Prognosis (14 papers). Samanta Cupini is often cited by papers focused on Colorectal Cancer Treatments and Studies (29 papers), Cancer Treatment and Pharmacology (19 papers) and Hepatocellular Carcinoma Treatment and Prognosis (14 papers). Samanta Cupini collaborates with scholars based in Italy, France and United States. Samanta Cupini's co-authors include Alfredo Falcone, Gianluca Masi, I. Brunetti, Giacomo Allegrini, Fotios Loupakis, M. Andreuccetti, Lorenzo Fornaro, E. Pfanner, Elisa Cerri and Franco Filipponi and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgery and The Lancet Oncology.

In The Last Decade

Samanta Cupini

34 papers receiving 940 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Samanta Cupini Italy 13 834 543 278 200 120 35 956
V. Picone Italy 4 825 1.0× 428 0.8× 314 1.1× 219 1.1× 71 0.6× 9 915
W. Evangelista Italy 4 849 1.0× 424 0.8× 303 1.1× 239 1.2× 71 0.6× 7 939
Marisa Di Seri Italy 9 631 0.8× 246 0.5× 260 0.9× 341 1.7× 94 0.8× 13 943
L. Vamvakas Greece 12 693 0.8× 209 0.4× 351 1.3× 102 0.5× 105 0.9× 48 807
S. Giachetti France 8 878 1.1× 399 0.7× 286 1.0× 218 1.1× 90 0.8× 9 1.1k
F. Maindrault-Gœbel France 12 1.0k 1.2× 330 0.6× 461 1.7× 405 2.0× 94 0.8× 22 1.2k
Michele Basso Italy 18 521 0.6× 292 0.5× 251 0.9× 150 0.8× 177 1.5× 47 839
Georgios Karagkounis United States 16 627 0.8× 294 0.5× 177 0.6× 310 1.6× 128 1.1× 45 841
Nicola Borsellino Italy 10 707 0.8× 226 0.4× 330 1.2× 188 0.9× 101 0.8× 19 880
Jian-Ming Xu China 12 578 0.7× 176 0.3× 341 1.2× 98 0.5× 167 1.4× 15 818

Countries citing papers authored by Samanta Cupini

Since Specialization
Citations

This map shows the geographic impact of Samanta Cupini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samanta Cupini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samanta Cupini more than expected).

Fields of papers citing papers by Samanta Cupini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samanta Cupini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samanta Cupini. The network helps show where Samanta Cupini may publish in the future.

Co-authorship network of co-authors of Samanta Cupini

This figure shows the co-authorship network connecting the top 25 collaborators of Samanta Cupini. A scholar is included among the top collaborators of Samanta Cupini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samanta Cupini. Samanta Cupini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pieri, Francesco, Julien Boetto, Andrea Giusti, et al.. (2025). Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib. The Oncologist. 30(7). 1 indexed citations
3.
Conca, Veronica, Roberto Moretto, Sara Lonardi, et al.. (2024). Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO.. Journal of Clinical Oncology. 42(16_suppl). TPS3644–TPS3644. 1 indexed citations
4.
Fanotto, V., Daniele Rossini, Mariaelena Casagrande, et al.. (2023). Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies. Cancers. 15(22). 5451–5451. 1 indexed citations
5.
Mazzanti, Chiara Maria, Mariangela Morelli, Sara Franceschi, et al.. (2023). P17.02.B CORRELATIONS BETWEEN CLINICAL BENEFIT TO SECOND LINE REGIMENS AND NADH-FLIM-BASED DRUG RESPONSE ASSESSMENT MODEL ON RECURRENT GBM PATIENT-DERIVED ORGANOIDS. Neuro-Oncology. 25(Supplement_2). ii116–ii117. 1 indexed citations
6.
Dell’Aquila, Emanuela, Daniele Rossini, Marco Stellato, et al.. (2022). Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO. Clinical Colorectal Cancer. 21(3). 220–228. 6 indexed citations
7.
8.
Moretto, Roberto, Daniele Rossini, Veronica Conca, et al.. (2021). CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. British Journal of Cancer. 125(6). 839–845. 10 indexed citations
9.
Salvatore, Lisa, Gianluca Masi, Fotios Loupakis, et al.. (2013). Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Receiving a First-Line Treatment Containing Bevacizumab: Update of Bebyp Trial by Gono. Annals of Oncology. 24. iv22–iv22. 2 indexed citations
10.
Cappuzzo, Federico, Andrea Sacconi, Lorenza Landi, et al.. (2013). MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies. Clinical Colorectal Cancer. 13(1). 37–45.e4. 45 indexed citations
11.
Masi, Gianluca, Fotios Loupakis, Lisa Salvatore, et al.. (2010). Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. The Lancet Oncology. 11(9). 845–852. 190 indexed citations
12.
Fornaro, Lorenzo, Giacomo Giulio Baldi, Gianluca Masi, et al.. (2010). Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. Critical Reviews in Oncology/Hematology. 78(3). 243–251. 19 indexed citations
13.
14.
Masi, Gianluca, Lorenzo Fornaro, Samanta Cupini, et al.. (2009). Refractory neuroendocrine tumor—response to liposomal doxorubicin and capecitabine. Nature Reviews Clinical Oncology. 6(11). 670–674. 3 indexed citations
15.
Vasile, Enrico, Gianluca Masi, Lorenzo Fornaro, et al.. (2009). A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. British Journal of Cancer. 100(11). 1720–1724. 31 indexed citations
16.
Masi, Gianluca, Lorenzo Marcucci, Fotios Loupakis, et al.. (2006). First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Annals of Oncology. 17(8). 1249–1254. 21 indexed citations
17.
Masi, Gianluca, Samanta Cupini, Lorenzo Marcucci, et al.. (2005). Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer. Annals of Surgical Oncology. 13(1). 58–65. 123 indexed citations
18.
Masi, Gianluca, Giacomo Allegrini, Samanta Cupini, et al.. (2004). First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Annals of Oncology. 15(12). 1766–1772. 93 indexed citations
19.
Allegrini, Giacomo, Alfredo Falcone, R. Di Marsico, et al.. (2004). 5-Fluorouracil Administered as a 48-Hour Semiintermittent Infusion in Combination With Leucovorin, Cisplatin and Epirubicin. American Journal of Clinical Oncology. 27(1). 101–105. 1 indexed citations
20.
Masi, Gianluca, Antonello Di Paolo, Giacomo Allegrini, et al.. (2001). A phase I and pharmacokinetic study of irinotecan given as a 7 days continuous infusion in metastatic colorectal cancer patients pretreated with 5-FU or raltitrexed. European Journal of Cancer. 37. S294–S295. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by V. Picone Breakdown of academic impact, for papers by W. Evangelista Breakdown of academic impact, for papers by Marisa Di Seri Breakdown of academic impact, for papers by L. Vamvakas Breakdown of academic impact, for papers by S. Giachetti Breakdown of academic impact, for papers by F. Maindrault-Gœbel Breakdown of academic impact, for papers by Michele Basso Breakdown of academic impact, for papers by Georgios Karagkounis Breakdown of academic impact, for papers by Nicola Borsellino Breakdown of academic impact, for papers by Jian-Ming Xu
Rankless by CCL
2026